New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%

Pressrelease - No. 6/2017

New analysis shows Soliqua ® 100/33 lowered HbA 1c by more than 2% in patients with screening levels greater than 9%

              

  • All subgroups treated with Soliqua ® 100/33 achieved a mean HbA 1c of
    less than 7% after 30 weeks

Copenhagen, June 10, 2017 -  Zealand Pharma's ("Zealand") partner Sanofi announced today that Soliqua ® 100/33 (insulin glargine and lixisenatide injection) 100 units/ml and 33 mcg/ml  lowered mean blood sugar levels (HbA 1c ) by 1.09-2.41% after 30 weeks in adults with type 2 diabetes previously treated with 15-40 units of basal insulin daily.

The abstract is entitled "iGlarLixi Reduces A 1c to a Greater Extent Than Basal Insulin Therapy Regardless of A 1c Levels at Screening" (Niemoeller E et al. Poster presentation 1079-P, American Diabetes Association (ADA) 77th Scientific Sessions, San Diego, CA, U.S., June 10). This new post-hoc analysis of data from the LixiLan-L Phase 3 study, which grouped participants according to HbA 1c level at screening, also showed that all subgroups achieved a mean HbA 1c of less than 7% during the study period. 1

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Soliqua ® 100/33 is an injectable prescription medicine that contains two diabetes medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults with type 2 diabetes when used in conjunction with diet and exercise in people who are not controlled with long-acting (basal) insulin (less than 60 units daily) or lixisenatide. Soliqua ® 100/33, which is intended to be used in conjunction with diet and exercise, is marketed as Suliqua ® in the EU.

For further information, please contact:
Britt Meelby Jensen , CEO and President
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom , Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin ® in the U.S. and as Lyxumia ® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus ® ) and is marketed as Soliqua ® 100/33 in the U.S. and has been approved as Suliqua ® in Europe and launched in the Netherlands.

Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).

06-17_0610 Soliqua_ADA



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via GlobeNewswire

HUG#2112322